Avid Bioservices partners with CIRM to provide CDMO services for CGT programs

Avid Bioservices announced a new partnership with the California Institute for Regenerative Medicine, CIRM, Industry Resource Partner Program. The collaboration is designed to support the advancement of manufacturing of adeno-associated adenovirus, AAV, as well as other cell and gene therapy, CGT, programs within the state of California. With $5.5 billion in funding from the state of California, CIRM is accelerating world-class science to deliver transformative regenerative medicine treatments in an equitable manner to a diverse California and world. Under terms of the partnership, Avid has joined the CIRM Industry Resource Partner Program to provide development and CGMP manufacturing services to CIRM-funded programs. The company will assist CIRM’s partners in accelerating gene therapy development and manufacturing through its suite of CDMO services, which span process and analytical development, cell banking, virus banking, drug substance manufacturing, and fill-finish activities. CIRM-funded programs will be offered access to Avid’s services in order to reduce the timelines required to advance through clinical development.